Stay updated on ALN-TTRSC SubQ Clinical Trial

Sign up to get notified when there's something new on the ALN-TTRSC SubQ Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ALN-TTRSC SubQ Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the data related to a Phase 1 clinical trial evaluating the safety and efficacy of ALN-TTRSC (revusiran) in healthy volunteers for the treatment of TTR-mediated Amyloidosis.
    Difference
    0.2%
    Check dated 2024-06-06T14:39:07.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, such as BMI range, non-childbearing status for females, and other health-related requirements. Previously, this section had no information provided.
    Difference
    20%
    Check dated 2024-05-22T21:35:05.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:59:52.000Z thumbnail image

Stay in the know with updates to ALN-TTRSC SubQ Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ALN-TTRSC SubQ Clinical Trial page.